Shukra Pharmaceuticals Ltd — Important, 03-10-2025: Company Update

The company's Board has approved a preferential issue of 46.43 lakh convertible equity warrants to its promoter shareholders. Each warrant, priced at Rs 34, allows subscription to one equity share, with the total issue aggregating to Rs 15.78 Cr. Investors will pay 25% upfront and the remaining 75% upon conversion within 18 months. This capital-raising move from promoters is subject to shareholder approval at an upcoming Extra-Ordinary General Meeting, which will also include the appointment of a scrutinizer.